GlassScriptPhysician profile
Heather R Kramer
NPI 1053648162
$1,131.55
in general payments reported to CMS, 2019-2025
24 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $17.02 · 2023: $601 · 2024: $101 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $201.12 | 2021-2023 | Kyprolis, Lumakras |
| Myriad Genetic Laboratories, INC. | $186.93 | 2023-2025 | Myrisk |
| Eisai INC. | $70.25 | 2023-2024 | |
| Glaxosmithkline, LLC. | $63.17 | 2021-2023 | |
| Janssen Biotech, INC. | $63.09 | 2021-2024 | |
| Pfizer INC. | $53.18 | 2023-2024 | |
| Emd Serono, INC. | $52.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $47.66 | 2021 | |
| Array Biopharma INC | $46.86 | 2023-2024 | Braftovi, Tukysa, Mektovi |
| Astrazeneca Pharmaceuticals LP | $39.68 | 2023 | Imfinzi |
| Merck Sharp & Dohme LLC | $31.99 | 2023 | Keytruda |
| Daiichi Sankyo INC. | $28.58 | 2025 | Datroway |
| Gilead Sciences, INC. | $28.32 | 2023 | Trodelvy |
| Mirati Therapeutics, INC. | $28.20 | 2023 | Krazati |
| Incyte Corporation | $27.45 | 2023 | Monjuvi, Pemazyre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $23.14 | 2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $20.45 | 2023 | Epkinly, Imbruvica |
| Taiho Oncology, INC. | $18.55 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.46 | 2025 | Ultomiris |
| Abbvie INC. | $17.02 | 2022 | |
| Stemline Therapeutics INC. | $16.84 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $16.47 | 2023 | Xpovio |
| Novartis Pharmaceuticals Corporation | $16.44 | 2025 | |
| Cti Biopharma Corp. | $16.19 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.